Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Royalty Pharma plc’s stock clocked out at $39.59, up 1.62% from its previous closing price of $38.96. In other words, the price has increased by $1.62 from its previous closing price. On the day, 4.08 million shares were traded. RPRX stock price reached its highest trading level at $40.0 during the session, while it also had its lowest trading level at $38.92.
Ratios:
To gain a deeper understanding of RPRX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 23.93 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.11. For the most recent quarter (mrq), Quick Ratio is recorded 3.48 and its Current Ratio is at 3.48. In the meantime, Its Debt-to-Equity ratio is 1.40 whereas as Long-Term Debt/Eq ratio is at 1.34.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Goldman on September 30, 2025, initiated with a Buy rating and assigned the stock a target price of $42.
On May 16, 2025, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $51.
UBS Downgraded its Buy to Neutral on June 03, 2024, while the target price for the stock was maintained at $28.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 11 ’25 when Norden Gregory sold 33,500 shares for $36.23 per share. The transaction valued at 1,213,749 led to the insider holds 194,848 shares of the business. Norden Gregory bought 33,500 shares of RPRX for $1,213,747 on Aug 11 ’25.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RPRX now has a Market Capitalization of 22852855808 and an Enterprise Value of 28131950592. As of this moment, Royalty’s Price-to-Earnings (P/E) ratio for their current fiscal year is 22.64, and their Forward P/E ratio for the next fiscal year is 8.28. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.52. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.72 while its Price-to-Book (P/B) ratio in mrq is 2.65. Its current Enterprise Value per Revenue stands at 11.972.
Stock Price History:
The Beta on a monthly basis for RPRX is 0.46, which has changed by 0.52306485 over the last 52 weeks, in comparison to a change of 0.15085125 over the same period for the S&P500. Over the past 52 weeks, RPRX has reached a high of $41.24, while it has fallen to a 52-week low of $24.05. The 50-Day Moving Average of the stock is 7.98%, while the 200-Day Moving Average is calculated to be 14.30%.
Shares Statistics:
It appears that RPRX traded 4.11M shares on average per day over the past three months and 5036650 shares per day over the past ten days. A total of 429.03M shares are outstanding, with a floating share count of 336.71M. Insiders hold about 21.19% of the company’s shares, while institutions hold 75.78% stake in the company. Shares short for RPRX as of 1761868800 were 14193421 with a Short Ratio of 3.46, compared to 1759190400 on 12866233. Therefore, it implies a Short% of Shares Outstanding of 14193421 and a Short% of Float of 3.3800002000000005.
Dividends & Splits
With its trailing 12-month dividend rate of 0.87, RPRX has a forward annual dividend rate of 0.87. Against a Trailing Annual Dividend Yield of 0.022330597. The stock’s 5-year Average Dividend Yield is 2.17.
Earnings Estimates
A comprehensive evaluation of Royalty Pharma plc (RPRX) is underway, with the input of 6.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $1.16, with high estimates of $1.16 and low estimates of $1.16.
Analysts are recommending an EPS of between $4.77 and $4.24 for the fiscal current year, implying an average EPS of $4.63. EPS for the following year is $5.05, with 7.0 analysts recommending between $5.45 and $4.53.
Revenue Estimates
In. The current quarter, 4 analysts expect revenue to total $829.22M. It ranges from a high estimate of $855.69M to a low estimate of $792M. As of. The current estimate, Royalty Pharma plc’s year-ago sales were $742MFor the next quarter, 4 analysts are estimating revenue of $825M. There is a high estimate of $825M for the next quarter, whereas the lowest estimate is $825M.
A total of 6 analysts have provided revenue estimates for RPRX’s current fiscal year. The highest revenue estimate was $3.24B, while the lowest revenue estimate was $3.08B, resulting in an average revenue estimate of $3.17B. In the same quarter a year ago, actual revenue was $2.8BBased on 6 analysts’ estimates, the company’s revenue will be $3.26B in the next fiscal year. The high estimate is $3.41B and the low estimate is $3.14B.
